Following on from information provided to NICE by the company in May 2020 the appraisal of Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy [ID940] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 940 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 November 2022 | Following on from information provided to NICE by the company in May 2020 the appraisal of Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy [ID940] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 15 November 2022 | Discontinued. Following on from information provided to NICE by the company in May 2020 the appraisal of Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy [ID940] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 25 June 2020 | Company have advised this technology in no longer in development. |
| 25 June 2020 | Suspended. Topic is suspended |
For further information on our processes and methods, please see our CHTE processes and methods manual